| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15B | 1.05B | 949.74M | 878.24M | 1.06B | 892.38M |
| Gross Profit | 1.14B | 1.04B | 934.72M | 862.74M | 1.05B | 880.07M |
| EBITDA | 1.11B | 947.11M | 810.84M | 1.00B | 992.70M | 715.64M |
| Net Income | 538.69M | 406.33M | 242.18M | 426.93M | 416.74M | 159.33M |
Balance Sheet | ||||||
| Total Assets | 10.60B | 9.90B | 9.12B | 9.41B | 9.64B | 9.50B |
| Cash, Cash Equivalents and Short-Term Investments | 737.19M | 518.34M | 442.81M | 297.10M | 20.53M | 163.53M |
| Total Debt | 4.99B | 4.84B | 5.07B | 5.29B | 5.25B | 5.17B |
| Total Liabilities | 5.35B | 5.17B | 5.36B | 5.60B | 5.53B | 5.46B |
| Stockholders Equity | 5.04B | 4.54B | 3.57B | 3.61B | 3.91B | 3.84B |
Cash Flow | ||||||
| Free Cash Flow | 840.89M | 749.43M | 617.74M | 578.51M | 627.07M | 633.14M |
| Operating Cash Flow | 876.55M | 749.43M | 617.74M | 625.73M | 722.14M | 708.26M |
| Investing Cash Flow | -809.16M | -671.16M | -770.00K | 442.85M | -524.17M | -89.06M |
| Financing Cash Flow | 345.62M | 26.32M | -473.31M | -789.45M | -341.12M | -485.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $8.11B | 27.07 | 8.13% | 3.56% | 59.25% | 88.37% | |
77 Outperform | $4.66B | 25.70 | 6.29% | 6.42% | 8.12% | 75.95% | |
76 Outperform | $12.99B | 24.70 | 11.28% | 6.10% | 13.50% | 31.56% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
64 Neutral | $9.03B | 341.83 | 1.12% | 2.10% | 11.81% | ― | |
58 Neutral | $11.35B | -283.51 | -0.48% | 7.63% | 9.58% | -111.99% | |
56 Neutral | $5.92B | -15.92 | -7.26% | 6.53% | -6.59% | 33.35% |
On November 3, 2025, Omega Healthcare Investors, Inc. announced a new ‘at-the-market’ equity offering sales agreement, allowing the issuance and sale of up to $2 billion in common stock. This agreement replaces a previous one from September 2024 and involves multiple financial institutions as sales agents, forward sellers, and forward purchasers. The sales will be conducted through various methods, including the New York Stock Exchange, and are subject to market conditions. This strategic move aims to enhance Omega Healthcare’s financial flexibility and market positioning, potentially impacting its stakeholders by providing additional capital for growth and operations.
On October 15, 2025, Omega Healthcare Investors, Inc. redeemed its $600 million 5.250% Senior Notes due 2026, originally issued in 2015. This action terminated the obligations under the Notes and the related Indenture, impacting Omega’s financial structure by discharging these debts.
On September 30, 2025, Omega Healthcare Investors, Inc. announced the closing of a new $2.3 billion senior unsecured credit facility, which includes a $2.0 billion revolving credit facility and a $300 million delayed draw term loan facility. This new facility replaces the previous $1.45 billion revolving credit facility and was supported by over 20 financial institutions, indicating strong market confidence. The credit facility is expected to support Omega’s refinancing, acquisitions, and other corporate purposes, potentially enhancing its market positioning and operational capabilities.
On September 15, 2025, Omega Healthcare Investors announced its decision to redeem all outstanding 5.250% Senior Notes due 2026 on October 15, 2025. This strategic move involves redeeming the notes at their principal amount plus accrued interest, potentially impacting the company’s financial operations and signaling a shift in its financial strategy.